RxDoctor Payments Data

Steven Farquhar, MD

Internal Medicine · Deridder, LANPI 1538153002

Payments from drug & device makers

$233in general payments, 2019–2025

Across 13 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$69
  • AbbVie$68
  • GSK$22
  • Axsome Therapeutics, Inc.$21
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21
  • Johnson & Johnson$17
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$233100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$233 in reported general payments places this provider in the 40th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$95,984
Medicare patients
98
Services billed
1,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban365$157,592
LinzessLinaclotide71$40,849
JardianceEmpagliflozin111$40,356
JanuviaSitagliptin Phosphate57$35,550
TrulicityDulaglutide26$35,044
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$32,094
RexultiBrexpiprazole41$30,039
TivicayDolutegravir Sodium13$28,395
EntrestoSacubitril/Valsartan42$21,147
MounjaroTirzepatide20$21,009
OzempicSemaglutide18$17,702
XareltoRivaroxaban18$16,450
ProcritEpoetin Alfa17$15,917
Atorvastatin Calcium1,100$13,516
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$13,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix$22$52,22799 claims
AbbVieLinzess$68$40,84971 claims
Johnson & JohnsonXarelto, Procrit$17$32,36735 claims
Novo NordiskOzempic$69$17,70218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Deridder

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →